Display options
Cite
Cardwell LA, Alinia H, Moradi Tuchayi S, et al. New developments in the treatment of rosacea - role of once-daily ivermectin cream. Clin Cosmet Investig Dermatol. 2016;9:71-7doi: 10.2147/CCID.S98091.
Cardwell, L. A., Alinia, H., Moradi Tuchayi, S., & Feldman, S. R. (2016). New developments in the treatment of rosacea - role of once-daily ivermectin cream. Clinical, cosmetic and investigational dermatology, 971-7. https://doi.org/10.2147/CCID.S98091
Cardwell, Leah A, et al. "New developments in the treatment of rosacea - role of once-daily ivermectin cream." Clinical, cosmetic and investigational dermatology vol. 9 (2016): 71-7. doi: https://doi.org/10.2147/CCID.S98091
Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR. New developments in the treatment of rosacea - role of once-daily ivermectin cream. Clin Cosmet Investig Dermatol. 2016 Mar 18;9:71-7. doi: 10.2147/CCID.S98091. eCollection 2016. PMID: 27051311; PMCID: PMC4807898.
Copy Download .nbib Format: NLM
Share it on

Clin Cosmet Investig Dermatol. 2016 Mar 18;9:71-7. doi: 10.2147/CCID.S98091. eCollection 2016.

New developments in the treatment of rosacea - role of once-daily ivermectin cream.

Clinical, cosmetic and investigational dermatology

Leah A Cardwell, Hossein Alinia, Sara Moradi Tuchayi, Steven R Feldman

Affiliations

  1. Department of Dermatology, Center for Dermatology Research, Winston-Salem, NC, USA.
  2. Department of Dermatology, Center for Dermatology Research, Winston-Salem, NC, USA; Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.

PMID: 27051311 PMCID: PMC4807898 DOI: 10.2147/CCID.S98091

Abstract

Rosacea is a chronic dermatological disorder with a variety of clinical manifestations localized largely to the central face. The unclear etiology of rosacea fosters therapeutic difficulty; however, subtle clinical improvement with pharmacologic treatments of various drug categories suggests a multifactorial etiology of the disease. Factors that may contribute to disease pathogenesis include immune abnormality, vascular abnormality, neurogenic dysregulation, presence of cutaneous microorganisms, UV damage, and skin barrier dysfunction. The role of ivermectin in the treatment of rosacea may be as an anti-inflammatory and anti-parasitic agent targeting Demodex mites. In comparing topical ivermectin and metronidazole, ivermectin was more effective; this treatment modality boasted more improved quality of life, reduced lesion counts, and more favorable participant and physician assessment of disease severity. Patients who received ivermectin 1% cream had an acceptable safety profile. Ivermectin is efficacious in decreasing inflammatory lesion counts and erythema.

Keywords: azelaic acid; metronidazole; papulopustular rosacea; topical; topical ivermectin

References

  1. J Dtsch Dermatol Ges. 2011 Jan;9(1):21-5 - PubMed
  2. J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):775-7 - PubMed
  3. J Am Acad Dermatol. 2015 Jul;73(1):138-143.e4 - PubMed
  4. J Am Acad Dermatol. 1998 Sep;39(3):502-4 - PubMed
  5. Br J Dermatol. 2004 Jun;150(6):1136-41 - PubMed
  6. Am J Clin Dermatol. 2000 May-Jun;1(3):191-9 - PubMed
  7. Clin Dermatol. 2010 Sep-Oct;28(5):478-82 - PubMed
  8. Case Rep Dermatol Med. 2014;2014:458046 - PubMed
  9. G Ital Dermatol Venereol. 2009 Dec;144(6):663-71 - PubMed
  10. J Drugs Dermatol. 2014 Jan;13(1):10-1 - PubMed
  11. Drugs. 2014 Sep;74(13):1457-65 - PubMed
  12. Cutis. 2007 Aug;80(2):149-51 - PubMed
  13. Br J Dermatol. 2015 Sep;173(3):651-62 - PubMed
  14. J Am Acad Dermatol. 2013 Oct;69(4):570-7 - PubMed
  15. J Dermatolog Treat. 2014 Aug;25(4):275-7 - PubMed
  16. J Dermatolog Treat. 2015;26(4):379-80 - PubMed
  17. J Am Acad Dermatol. 2001 Nov;45(5):723-30 - PubMed
  18. Cutis. 2013 Dec;92(6):306-17 - PubMed
  19. Cutis. 2007 Jan;79(1):73-80 - PubMed
  20. J Drugs Dermatol. 2014 Nov;13(11):1380-6 - PubMed
  21. J Am Acad Dermatol. 2004 Feb;50(2):266-72 - PubMed
  22. Br J Dermatol. 2015 Apr;172(4):1103-10 - PubMed
  23. J Drugs Dermatol. 2009 Jul;8(7):639-48 - PubMed
  24. Arch Dermatol. 2003 Nov;139(11):1444-50 - PubMed
  25. Med Lett Drugs Ther. 2015 Apr 13;57(1466):51-2 - PubMed
  26. J Am Acad Dermatol. 2013 Dec;69(6 Suppl 1):S15-26 - PubMed
  27. Arch Dermatol. 1987 May;123(5):609-14 - PubMed
  28. J Eur Acad Dermatol Venereol. 2012 Jan;26(1):19-28 - PubMed
  29. An Bras Dermatol. 2012 Nov-Dec;87(6):903-5 - PubMed
  30. J Am Acad Dermatol. 2015 May;72(5):749-58; quiz 759-60 - PubMed
  31. J Drugs Dermatol. 2008 Jun;7(6):541-6 - PubMed
  32. J Am Acad Dermatol. 2003 Jun;48(6):836-45 - PubMed
  33. J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):961-5 - PubMed
  34. J Drugs Dermatol. 2014 Mar;13(3):316-23 - PubMed
  35. J Am Acad Dermatol. 2013 Dec;69(6 Suppl 1):S57-65 - PubMed
  36. J Am Acad Dermatol. 2015 May;72(5):761-70; quiz 771-2 - PubMed
  37. JAMA Dermatol. 2014 Jan;150(1):61-3 - PubMed
  38. Drugs Today (Barc). 2015 Apr;51(4):243-50 - PubMed
  39. Cutis. 2006 Apr;77(4 Suppl):3-11 - PubMed
  40. J Med Microbiol. 2012 Nov;61(Pt 11):1504-10 - PubMed

Publication Types